| Citation: |
CHEN Xiaoxue, LI Ran, ZHU Huijuan, LU Lin. Advances in Hormone Replacement Therapy for Adult Adrenal Insufficiency[J]. Journal of Rare Diseases, 2023, 2(3): 436-441. DOI: 10.12376/j.issn.2097-0501.2023.03.016
|
Adrenal insufficiency is a disease characterized by insufficient secretion of adrenocortical hormones, usually treated with glucocorticoid replacement therapy. The routine drugs have two forms-short-acting and long-acting. The shorter one should be taken 2-3 times a day resulting hormone level of patients fluctuating greatly within a day. Although long-acting drugs reduce the frequency of administration, it is easy to lead to excessive replacement, resulting in adverse effects on metabolism. New alternative treatments for adult patients have emerged, including modified-release hydrocortisone and hydrocortisone subcutaneous infusion pumps. In this review, we briefly introduce these new therapies, emphasizing the pharmacodynamics and pharmacokinetics of the replacement, the effects on metabolism and drug safety, aiming at contributing to the future clinical practice.
| [1] |
Hahner S, Ross RJ, Arlt W, et al. Adrenal insufficiency[J]. Nat Rev Dis Primers, 2021, 7(1): 19. doi: 10.1038/s41572-021-00252-7
|
| [2] |
Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis[J]. N Engl J Med, 2019, 381(9): 852-861. doi: 10.1056/NEJMra1807486
|
| [3] |
Nowotny H, Ahmed SF, Bensing S, et al. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis[J]. Endocrine, 2021, 71(3): 586-594. doi: 10.1007/s12020-021-02649-6
|
| [4] |
Auer MK, Paizoni L, Hofbauer LC, et al. Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency[J]. J Steroid Biochem Mol Biol, 2020, 204: 105734. doi: 10.1016/j.jsbmb.2020.105734
|
| [5] |
Quinkler M, Ekman B, Marelli C, et al. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency[J]. Endocr Connect, 2017, 6(1): 1-8. doi: 10.1530/EC-16-0081
|
| [6] |
Husebye ES, Pearce SH, Krone NP, et al. Adrenal insufficiency[J]. Lancet, 2021, 397(10274): 613-629. doi: 10.1016/S0140-6736(21)00136-7
|
| [7] |
Buning JW, Touw DJ, Brummelman P, et al. Pharmacokinetics of oral hydrocortisone-results and implications from a randomized controlled trial[J]. Metabolism, 2017, 71: 7-16. doi: 10.1016/j.metabol.2017.02.005
|
| [8] |
Johannsson G, Bergthorsdottir R, Nilsson AG, et al. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study[J]. Eur J Endocrinol, 2009, 161(1): 119-130. doi: 10.1530/EJE-09-0170
|
| [9] |
Whitaker M, Debono M, Huatan H, et al. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure[J]. Clin Endocrinol (Oxf), 2014, 80(4): 554-561. doi: 10.1111/cen.12316
|
| [10] |
Bannon CAM, Border D, Hanson P, et al. Early metabolic benefits of switching hydrocortisone to modified release hydrocortisone in adult adrenal insufficiency[J]. Front Endocrinol (Lausanne), 2021, 12: 641247. doi: 10.3389/fendo.2021.641247
|
| [11] |
Gasco V, Giannelli J, Campioni L, et al. Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency[J]. J Endocrinol Invest, 2023, 46(3): 587-597.
|
| [12] |
Dineen R, Martin-Grace J, Ahmed KMS, et al. Cardiometabolic and psychological effects of dual-release hydrocorti-sone: a cross-over study[J]. Eur J Endocrinol, 2021, 184(2): 253-265. doi: 10.1530/EJE-20-0642
|
| [13] |
Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment[J]. Nat Rev Endocrinol, 2020, 16(8): 437-447. doi: 10.1038/s41574-020-0341-0
|
| [14] |
Frara S, Chiloiro S, Porcelli T, et al. Bone safety of dual-release hydrocortisone in patients with hypopituitarism[J]. Endocrine, 2018, 60(3): 528-531. doi: 10.1007/s12020-017-1512-1
|
| [15] |
Guarnotta V, Di Stefano C, Giordano C. Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency[J]. Sci Rep, 2022, 12(1): 13280. doi: 10.1038/s41598-022-13506-5
|
| [16] |
Espiard S, McQueen J, Sherlock M, et al. Improved urinary cortisol metabolome in addison disease: a prospective trial of dual-release hydrocortisone[J]. J Clin Endocrinol Metab, 2021, 106(3): 814-825. doi: 10.1210/clinem/dgaa862
|
| [17] |
Boesen VB, Borresen SW, Christoffersen T, et al. The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments[J]. Endocrine, 2021, 71(2): 467-475. doi: 10.1007/s12020-020-02507-x
|
| [18] |
Nilsson AG, Marelli C, Fitts D, et al. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency[J]. Eur J Endocrinol, 2014, 171(3): 369-377. doi: 10.1530/EJE-14-0327
|
| [19] |
Løvås K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease[J]. Eur J Endocrinol, 2007, 157(1): 109-112. doi: 10.1530/EJE-07-0052
|
| [20] |
Zhang L, Cai K, Wang Y, et al. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men[J]. Am J Mens Health, 2019, 13(1): 1557988318818280.
|
| [21] |
Puig-Domingo M, Díaz G, Nicolau J, et al. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide[J]. Eur J Endocrinol, 2008, 159(5): 653-657. doi: 10.1530/EJE-08-0269
|
| [22] |
Merza Z, Rostami-Hodjegan A, Memmott A, et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia[J]. Clin Endocrinol (Oxf), 2006, 65(1): 45-50. doi: 10.1111/j.1365-2265.2006.02544.x
|
| [23] |
Melikyan MA, Gubaeva DN, Kareva MA. Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism[J]. Probl Endokrinol (Mosk), 2020, 66(3): 81-87. doi: 10.14341/probl12421
|
| [24] |
Gagliardi L, Nenke MA, Thynne TR, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial[J]. J Clin Endocrinol Metab, 2014, 99(11): 4149-4157. doi: 10.1210/jc.2014-2433
|
| [25] |
Oksnes M, Björnsdottir S, Isaksson M, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial[J]. J Clin Endocrinol Metab, 2014, 99(5): 1665-1674. doi: 10.1210/jc.2013-4253
|
| [26] |
Cardini F, Torlone E, Bini V, et al. Continuous subcu-taneous hydrocortisone infusion in a woman with secondary adrenal insufficiency[J]. Endocrine, 2019, 63(2): 398-400. doi: 10.1007/s12020-018-1780-4
|
| [27] |
Kalafatakis K, Russell GM, Harmer CJ, et al. Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man[J]. Proc Natl Acad Sci USA, 2018, 115(17): E4091-E4100.
|
| [28] |
Violaris IG, Kalafatakis K, Zavala E, et al. Modelling hydrocortisone pharmacokinetics on a subcutaneous pulsatile infusion replacement strategy in patients with adrenocortical insufficiency[J]. Pharmaceutics, 2021, 13(6): 769. doi: 10.3390/pharmaceutics13060769
|
| [29] |
Björnsdottir S, Øksnes M, Isaksson M, et al. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy[J]. Clin Endocrinol (Oxf), 2015, 83(1): 28-35. doi: 10.1111/cen.12670
|
| [30] |
Khanna A, Khurana R, Kyriacou A, et al. Management of adrenocortical insufficiency with continuous subcutaneous hydrocortisone infusion: long-term experience in three patients[J]. Endocrinol Diabetes Metab Case Rep, 2015, 2015: 150005.
|
| [1] | Hypothalamic and Pituitary Disease Group of China Alliance for Rare Diseases. Chinese Experts′ Consensus on the Management of Hypothalamic Obesity Secondary to Sellar Lesions[J]. Journal of Rare Diseases, 2024, 3(4): 479-491. DOI: 10.12376/j.issn.2097-0501.2024.04.011 |
| [2] | CHEN Yu, LI Jianwei, TAN Huiwen, YU Yerong. A Case Report of Marfan Syndrome with Pituitary Tumor Which Could be Misdiagnosed as Gigantism[J]. Journal of Rare Diseases, 2024, 3(2): 237-240. DOI: 10.12376/j.issn.2097-0501.2024.02.013 |
| [3] | JIN Yuanmeng, ZHANG Chunli, XU Jing, XIE Jingyuan. A Case Report of MYH9 Gene Mutation Associated with Glomerular Minor Lesion[J]. Journal of Rare Diseases, 2024, 3(1): 131-135. DOI: 10.12376/j.issn.2097-0501.2024.01.018 |
| [4] | CAO Yaqing, GUO Baocheng, NIE Min. Genotype-Phenotype Correlation Analysis of WT1 Gene Variants in Denys-Drash Syndrome and Frasier Syndrome[J]. Journal of Rare Diseases, 2024, 3(1): 63-76. DOI: 10.12376/j.issn.2097-0501.2024.01.009 |
| [5] | CHEN Dan, SUN Liying, ZHONG Wenyao, TIAN Wen. A Case Report of Nail-Patella Syndrome[J]. Journal of Rare Diseases, 2023, 2(4): 611-615. DOI: 10.12376/j.issn.2097-0501.2023.04.018 |
| [6] | LI Guozhuang, XU Kexin, ZHAO Sen, ZHANG Jianguo, QIU Guixing, SUI Ruifang, WANG Tao, SHEN Min, ZENG Xuejun, WANG Wei, MA Mingsheng, WEI Min, LONG Xiao, LYU Ke, HUO Li, XUAN Lei, WU Nan. A Case Report of Blau Syndrome[J]. Journal of Rare Diseases, 2023, 2(4): 547-553. DOI: 10.12376/j.issn.2097-0501.2023.04.012 |
| [7] | ZHAO Yuxing, DUAN Lian, LYU Wei, YAO Yong, YOU Hui, ZHANG Wen, MA Jin, MAO Xinxin, ZHU Huijuan. Rare Manifestations of Common Diseases: Middle-Aged Male Polyuria-Headache-Inflammatory Granulomatous Lesions[J]. Journal of Rare Diseases, 2023, 2(3): 359-364. DOI: 10.12376/j.issn.2097-0501.2023.03.007 |
| [8] | Chinese Research Hospital Association- Children's Oncology Committee, FUTang Research Center of Pediatric Development- Children's Oncology Committee, FUTang Research Center of Pediatric Development- Children's Neurology Committee. Recommendations for Neuroblastoma Associated Opsoclonus-myoclonus-ataxia Syndrome in Childhood[J]. Journal of Rare Diseases, 2022, 1(3): 304-310. DOI: 10.12376/j.issn.2097-0501.2022.03.012 |
| [9] | ZHONG Linqing, MA Mingsheng, SUI Ruifang, HONG Xia, FENG Feng, HUO Li, DAI Menghua, XU Qiang, SONG Hongmei. Multidisciplinary Treatment on a Case of ROSAH Syndrome[J]. Journal of Rare Diseases, 2022, 1(3): 289-295. DOI: 10.12376/j.issn.2097-0501.2022.03.010 |
| [10] | HONG Yuehui, SHEN Min, WANG Tao, MA Mingsheng, ZHAO Sen, FENG Feng, ZHAO Dachun, ZHANG Wen, ZENG Xuejun, XUAN Lei, YAO Ming, ZHU Yicheng. An Adolescent with Recurrent Intracranial Hemorrhage, and Skin Lesion[J]. Journal of Rare Diseases, 2022, 1(2): 151-157. DOI: 10.12376/j.issn.2097-0501.2022.02.009 |
| 1. |
张牧秋，汪盛. 坏死松解性游走性红斑1例. 中国皮肤性病学杂志. 2025(01): 105-108 .
|
Official account
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Author
Peer Review
Editorial Entry
Editor Work
DownLoad: